58
Participants
Start Date
February 25, 2022
Primary Completion Date
May 31, 2026
Study Completion Date
July 31, 2026
ES104
ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
ES104
ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
ES104
ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Beijing Cancer Hospital, Beijing
Elpiscience (Suzhou) Biopharma, Ltd.
INDUSTRY